speb/financial-data huggingface dataset:
EXPL.PA income_statement (annual, 2025-12-31) — Cost Of Revenue: 336110000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Current Assets: 275286000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Current Assets: 275286000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 10162000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 10162000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Current Debt: 24729000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Current Debt: 24729000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 34891000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 34891000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Current Liabilities: 193579000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 193579000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Current Provisions: 2017000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Current Provisions: 2017000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Deferred Tax: 5445000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Depreciation: 30828000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 30828000.00
EXPL.PA income_statement (annual, 2025-12-31) — Depreciation And Amortization In Income Statement: 30076000.00
EXPL.PA income_statement (annual, 2025-12-31) — Depreciation Income Statement: 30076000.00
EXPL.PA income_statement (annual, 2025-12-31) — Diluted Average Shares: 2141918.00
EXPL.PA income_statement (annual, 2025-12-31) — Diluted EPS: 13.31
EXPL.PA income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 28515000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Dividend Received Cfo: 9668000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Dividends Received Cfi: 28000.00
EXPL.PA income_statement (annual, 2025-12-31) — EBIT: 42504000.00
EXPL.PA income_statement (annual, 2025-12-31) — EBITDA: 73332000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: -1142000.00
EXPL.PA cash_flow (annual, 2025-12-31) — End Cash Position: 37865000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Financial Assets: 853000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Financial Assets: 853000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Financing Cash Flow: -11344000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Finished Goods: 26559000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Finished Goods: 26559000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Free Cash Flow: 30884000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Gain Loss On Investment Securities: -1000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Goodwill: 17411000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Goodwill: 17411000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 23392000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 23392000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Gross Accounts Receivable: 143195000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Gross Accounts Receivable: 143195000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Gross PPE: 392717000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Gross PPE: 392717000.00
EXPL.PA income_statement (annual, 2025-12-31) — Gross Profit: 203101000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Held To Maturity Securities: 1287000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Held To Maturity Securities: 1287000.00
EXPL.PA income_statement (annual, 2025-12-31) — Impairment Of Capital Assets: 0.00
EXPL.PA income_statement (annual, 2025-12-31) — Interest Expense: 6662000.00
EXPL.PA income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 6662000.00
EXPL.PA income_statement (annual, 2025-12-31) — Interest Income: 37000.00
EXPL.PA income_statement (annual, 2025-12-31) — Interest Income Non Operating: 37000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Interest Paid Cff: -6495000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Inventories Adjustments Allowances: -1931000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Inventories Adjustments Allowances: -1931000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Inventory: 63856000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Inventory: 63856000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Invested Capital: 275800000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Invested Capital: 275800000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Investing Cash Flow: -36621000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Investmentin Financial Assets: 1353000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Investmentin Financial Assets: 1353000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Issuance Of Debt: 32817000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Land And Improvements: 90865000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 90865000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 18892000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 18892000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Long Term Debt: 63384000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 63384000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 82276000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 82276000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 31077000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Long Term Debt Payments: 0.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Long Term Equity Investment: 39123000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Long Term Equity Investment: 39123000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Long Term Provisions: 21024000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Long Term Provisions: 21024000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Minority Interest: 10180000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Minority Interest: 10180000.00
EXPL.PA income_statement (annual, 2025-12-31) — Minority Interests: -1882000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Net Debt: 48065000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Net Debt: 48065000.00
EXPL.PA income_statement (annual, 2025-12-31) — Net Income: 28515000.00
EXPL.PA income_statement (annual, 2025-12-31) — Net Income Common Stockholders: 28515000.00
EXPL.PA income_statement (annual, 2025-12-31) — Net Income Continuous Operations: 30397000.00
EXPL.PA income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 28515000.00
EXPL.PA income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 28515000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 30397000.00
EXPL.PA income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 30397000.00
EXPL.PA income_statement (annual, 2025-12-31) — Net Interest Income: -5794000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: 11394000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: 31077000.00
EXPL.PA income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -5794000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Net Other Financing Charges: 319000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Net Other Investing Changes: -9732000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Net PPE: 164459000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Net PPE: 164459000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -26895000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Net Short Term Debt Issuance: -19683000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 164295000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 164295000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 8368000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 8368000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 2484000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 2484000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 13062000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 13062000.00
EXPL.PA income_statement (annual, 2025-12-31) — Normalized EBITDA: 74705000.00
EXPL.PA income_statement (annual, 2025-12-31) — Normalized Income: 29679418.31
EXPL.PA cash_flow (annual, 2025-12-31) — Operating Cash Flow: 59001000.00
EXPL.PA income_statement (annual, 2025-12-31) — Operating Income: 36369000.00
EXPL.PA income_statement (annual, 2025-12-31) — Operating Revenue: 539211000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 2133383.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 2133383.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Other Current Assets: 11983000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 11983000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 6954000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 6954000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 5981000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 5981000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Other Non Cash Items: 6543000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 2546000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 2546000.00
EXPL.PA income_statement (annual, 2025-12-31) — Other Operating Expenses: 6516000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Other Payable: 28025000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Other Payable: 28025000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Other Properties: 267274000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Other Properties: 267274000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Other Receivables: 2872000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Other Receivables: 2872000.00
EXPL.PA income_statement (annual, 2025-12-31) — Other Special Charges: 1376000.00
EXPL.PA income_statement (annual, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Payables: 141003000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Payables: 141003000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Prepaid Assets: 2694000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 2694000.00
EXPL.PA income_statement (annual, 2025-12-31) — Pretax Income: 35842000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Properties: 0.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
EXPL.PA cash_flow (annual, 2025-12-31) — Provisionand Write Offof Assets: -1327000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Purchase Of PPE: -28117000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Raw Materials: 32697000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Raw Materials: 32697000.00
EXPL.PA income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 336110000.00
EXPL.PA income_statement (annual, 2025-12-31) — Reconciled Depreciation: 30828000.00
EXPL.PA income_statement (annual, 2025-12-31) — Rent Expense Supplemental: 15776000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Repayment Of Debt: -21423000.00
EXPL.PA income_statement (annual, 2025-12-31) — Restructuring And Mergern Acquisition: -3000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Retained Earnings: 28515000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Retained Earnings: 28515000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Sale Of PPE: 1222000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Share Issued: 2262830.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Share Issued: 2262830.00
EXPL.PA cash_flow (annual, 2025-12-31) — Short Term Debt Issuance: 1740000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Short Term Debt Payments: -21423000.00
EXPL.PA income_statement (annual, 2025-12-31) — Special Income Charges: -1373000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Stock Based Compensation: 0.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Stockholders Equity: 187687000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 187687000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Tangible Book Value: 164295000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 164295000.00
EXPL.PA income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -208581.69
EXPL.PA income_statement (annual, 2025-12-31) — Tax Provision: 5445000.00
EXPL.PA income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.15
EXPL.PA balance_sheet (annual, 2025-12-31) — Taxes Receivable: 20895000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 20895000.00
EXPL.PA cash_flow (annual, 2025-12-31) — Taxes Refund Paid: -4783000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Total Assets: 512838000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Total Assets: 512838000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Total Capitalization: 251071000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 251071000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Total Debt: 117167000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Total Debt: 117167000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 197867000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 197867000.00
EXPL.PA income_statement (annual, 2025-12-31) — Total Expenses: 502842000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 314971000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 314971000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 237552000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 237552000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 121392000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 121392000.00
EXPL.PA income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 42939000.00
EXPL.PA income_statement (annual, 2025-12-31) — Total Other Finance Cost: -831000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Total Tax Payable: 28617000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 28617000.00
EXPL.PA income_statement (annual, 2025-12-31) — Total Unusual Items: -1373000.00
EXPL.PA income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -1373000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Treasury Shares Number: 129447.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 129447.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Treasury Stock: 2450000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Treasury Stock: 2450000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Work In Process: 6531000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Work In Process: 6531000.00
EXPL.PA balance_sheet (annual, 2025-12-31) — Working Capital: 81707000.00
EXPL.PA balance_sheet (quarterly, 2025-12-31) — Working Capital: 81707000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -309390000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 11300000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -850000.00
EXPLEOSOL.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 2330000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Available For Sale Securities: 16090000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 858940000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 290610000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 1440190000.00
EXPLEOSOL.NS cash_flow (annual, 2022-03-31) — Change In Inventory: -22700000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Construction In Progress: 60620000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Current Debt: 780000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Current Deferred Taxes Liabilities: 89130000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Dividends Payable: 1920000.00
EXPLEOSOL.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 1647590000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Goodwill: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 1737980000.00
EXPLEOSOL.NS income_statement (annual, 2022-03-31) — Interest Income: 24720000.00
EXPLEOSOL.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 24720000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Inventory: 22700000.00
EXPLEOSOL.NS cash_flow (annual, 2022-03-31) — Issuance Of Debt: 4570000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Long Term Debt: 4570000.00
EXPLEOSOL.NS cash_flow (annual, 2022-03-31) — Long Term Debt Issuance: 4570000.00
EXPLEOSOL.NS cash_flow (annual, 2022-03-31) — Long Term Debt Payments: -5240000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 508290000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Minority Interest: 0.00
EXPLEOSOL.NS cash_flow (annual, 2022-03-31) — Net Issuance Payments Of Debt: -670000.00
EXPLEOSOL.NS cash_flow (annual, 2022-03-31) — Net Long Term Debt Issuance: -670000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Taxes Liabilities: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Other Payable: 358650000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Other Receivables: 610190000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 116440000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 319530000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
EXPLEOSOL.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 9110000.00
EXPLEOSOL.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 9110000.00
EXPLEOSOL.NS cash_flow (annual, 2022-03-31) — Repayment Of Debt: -5240000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 33860000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 4732360000.00
EXPLEOSOL.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 63910000.00
EXPLEOSOL.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 1711500000.00
EXPLEOSOL.NS balance_sheet (annual, 2022-03-31) — Work In Process: 22700000.00
EXPLEOSOL.NS income_statement (annual, 2022-03-31) — Write Off: 0.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — +Operating Expense: 2710470000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — +Total Revenue: 9032950000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 638390000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 2394100000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -437340000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 11300000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -5070000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 15519739.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Basic EPS: 86.27
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 1730800000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 1000680000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -441950000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 257870000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 1525310000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 1526050000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 380010000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 1145300000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Change In Inventory: 22700000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: -363450000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: -4220000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Change In Payable: -74400000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -976620000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -1450710000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Changes In Cash: -194780000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Common Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 5302320000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 60620000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 4589220000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Current Assets: 5527860000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 39110000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Current Debt: 780000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 39890000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Current Deferred Taxes Liabilities: 146940000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 1677350000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 30230000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Depreciation: 278840000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 278840000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 278840000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 278840000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 15519739.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Diluted EPS: 86.27
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 1338880000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 1380000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — EBIT: 1883620000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — EBITDA: 2162460000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Effect Of Exchange Rate Changes: -10710000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — End Cash Position: 1525310000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -65710000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: -211140000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: -8470000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 1420880000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Goodwill: 19000000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 267360000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 2399170000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 1650620000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Gross Profit: 4443730000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Interest Expense: 22560000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 22560000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Interest Income: 40460000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 40460000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -13610000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 39530000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Inventory: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 5307030000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -359880000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 41550000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 218760000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 3930000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 222690000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 0.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -640000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 93750000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 589320000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Minority Interest: 0.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Minority Interests: 0.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: 17010000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Net Income: 1338880000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 1338880000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 1338880000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 1338880000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 1338880000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 1861060000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 1338880000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Net Interest Income: 17900000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: 33160000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: -640000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: -640000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: 17900000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Net PPE: 1213280000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -432570000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 5034960000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 6170000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 93750000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 293780000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 2160950000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Normalized Income: 1337793678.87
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 230810000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Operating Income: 1733260000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Operating Revenue: 9032950000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 10252485.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 684520000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 133970000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 1310000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 248360000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: -17890000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 158650000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 1220000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 630660000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Other Payable: 287200000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Other Properties: 1152660000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 1106730000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 740000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Other Special Charges: -8470000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Payables: 926970000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 142730000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 469940000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Pretax Income: 1861060000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 11180000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -1885930000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -441950000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 4589220000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 278840000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 9350000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 9350000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -640000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 31040000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 6088900000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 1919090000.00
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 9380000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 78290000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 1499170000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Share Issued: 10252485.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Special Income Charges: 1510000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 5302320000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 5034960000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 423678.87
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Tax Provision: 522180000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.28
EXPLEOSOL.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -460210000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Total Assets: 7302280000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 5306250000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Total Debt: 262580000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 5302320000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Total Expenses: 7299690000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 1999960000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 1774420000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 322610000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 146940000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 1510000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 1510000.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Work In Process: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2023-03-31) — Working Capital: 3850510000.00
EXPLEOSOL.NS income_statement (annual, 2023-03-31) — Write Off: 6960000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — +Operating Expense: 3023150000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — +Total Revenue: 9648700000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 276810000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 2493560000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -606390000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 11300000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -13180000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Amortization: 101340000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 101340000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 15519739.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Basic EPS: 58.27
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 1525310000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 1050480000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -174830000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 260560000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 1761380000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 1961970000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -77600000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 401440000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 1359940000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Change In Inventory: 0.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: 123570000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: -79140000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Change In Payable: -348150000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -152360000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -406920000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 248240000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Common Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 6111510000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 45440000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 5476730000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Current Assets: 5976980000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 50740000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Current Debt: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 50740000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Current Deferred Taxes Liabilities: 58600000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 1036240000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 71160000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Depreciation: 235320000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 336660000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 336660000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 235320000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 15519739.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Diluted EPS: 58.27
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 904390000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 980000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — EBIT: 1221830000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — EBITDA: 1558490000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: -12170000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — End Cash Position: 1761380000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -152010000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 538630000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -280000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 1720000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 1444300000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Goodwill: 19000000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 251000000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 2506740000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 1715090000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Gross Profit: 4171970000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Hedging Assets Current: 0.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Interest Expense: 26090000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 26090000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Interest Income: 69370000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 69370000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -24820000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 54070000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 6111510000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -313210000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 38190000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 209820000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 209820000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -4710000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 104260000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 619170000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 0.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Minority Interests: 0.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: 34690000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Net Income: 904390000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 904390000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 904390000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 904390000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 904390000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 1195740000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 904390000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Net Interest Income: 43280000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -197530000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: -4710000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -4710000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: 43280000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Net PPE: 1108700000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -169750000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 5860510000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 39550000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 289970000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 230810000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 1560330000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Normalized Income: 905781671.77
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 713460000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Operating Income: 1148820000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Operating Revenue: 9648700000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 15519739.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 617900000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: -10000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 1310000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 232000000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: -43280000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 40460000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 10000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 50000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 825220000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Other Payable: 368650000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Other Properties: 1063240000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 1096640000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 200590000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Other Special Charges: 1720000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Payables: 646440000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 71160000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 395860000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Pretax Income: 1195740000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 10350000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -4995510000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -174830000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 5476730000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 336660000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 22820000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 22820000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -4710000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 28950000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 6899400000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 4797980000.00
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 5080000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 59450000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 1503750000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Share Issued: 15519739.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Special Income Charges: -2120000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 6111510000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 5860510000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: -448328.23
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Tax Provision: 291350000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.24
EXPLEOSOL.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -415220000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Total Assets: 7647550000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 6111510000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Total Debt: 260560000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 6111510000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Total Expenses: 8499880000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 1536040000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 1670570000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 499800000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 58600000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Total Unusual Items: -1840000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: -1840000.00
EXPLEOSOL.NS balance_sheet (annual, 2024-03-31) — Working Capital: 4940740000.00
EXPLEOSOL.NS income_statement (annual, 2024-03-31) — Write Off: 400000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 718750000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 2601500000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 328570000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 2736930000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 3397470000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 6705750000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 0.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 6954930000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 70150000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 70150000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 1459580000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 88190000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 19000000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 198830000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 1139780000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 6705750000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 79880000.00